p53 targets chromatin structure alteration to repress alpha-fetoprotein gene expression

Stacey K. Ogden1, 2, Kathleen C. Lee1, 5, Kara Wernke-Dollries2, Sabrina A. Stratton4, Bruce Aronow3 and Michelle Craig Barton*2, 4

2Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati and 3Children's Hospital Research Foundation, Cincinnati, OH, 4Department of Biochemistry and Molecular Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX

1Equally contributing authors

5Current address:
Department of Molecular Biology and Genetics
Cornell University
467 Biotechnology Building
Ithaca, NY 14853

*Corresponding author:
Michelle C. Barton
Department of Biochemistry and Molecular Biology
University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd., Box 117
Houston, TX 77030
E-mail: mbarton@odin.mdacc.tmc.edu

Running title: p53 modifies chromatin independently of histone acetylation
Summary

Many of the functions ascribed to p53 tumor suppressor protein are mediated through transcription regulation. We have shown that p53 represses hepatic-specific alpha-fetoprotein (AFP) gene expression by direct interaction with a composite HNF-3/p53 DNA binding element. Using solid-phase, chromatin-assembled AFP DNA templates and analysis of chromatin structure and transcription in vitro, we find that p53 binds DNA and alters chromatin structure at the AFP core promoter to regulate transcription. Chromatin assembled in the presence of hepatoma extracts is activated for AFP transcription with an open, accessible core promoter structure. Distal (-850) binding of p53 during chromatin assembly, but not post-assembly, reverses transcription activation concomitant with promoter inaccessibility to restriction enzyme digestion. Inhibition of histone deacetylase activity by trichostatin-A (TSA) addition, prior to and during chromatin assembly, activated chromatin transcription in parallel with increased core promoter accessibility. Chromatin immunoprecipitation (ChIP) analyses showed increased H3 and H4 acetylated histones at the core promoter in the presence of TSA, while histone acetylation remained unchanged at the site of distal p53 binding. Our data reveal that p53 targets chromatin structure alteration at the core promoter, independently of effects on histone acetylation, to establish repressed AFP gene expression.
**Introduction**

The tumor suppressor protein p53 plays central roles in the regulation of cell growth, cell cycle arrest and apoptosis. It is activated in response to a variety of DNA damaging agents and has been shown to interact with a number of cellular proteins of both mammalian and viral origins. In general, the functional consequence of p53 DNA binding is transcription activation of target genes with role(s) in cellular stress response, as well as certain developmental pathways (reviewed in 1,2-5). More recently, however, examples of p53-mediated transcription repression through sequence-specific DNA binding have been reported (6-9).

We have established that p53 binds within the AFP distal developmental repressor region, displacing bound trans-activator HNF-3 (FoxA) protein, and contributes to post-natal, tissue-specific repression of AFP (6). AFP is normally expressed at high levels in the liver of the developing fetus and silenced after birth. Adult expression of AFP is monitored as a tumor marker: aberrant reactivation occurs in up to 85% of all hepatocellular carcinoma cases (reviewed in 10).

In this study, we find that p53 binds to DNA during chromatin structure organization as an obligate step in transcription repression. DNA binding of p53 mediates distal regulation of AFP transcription through alteration of chromatin structure at the core promoter. The ability of p53 to regulate nucleosome positioning at the core promoter is independent of histone modification. We show that histone hyperacetylation has direct consequences for core promoter chromatin accessibility and gene activation. These effects are overridden by addition of p53, which represses transcription by restricting chromatin accessibility even in the presence of hyperacetylated histone H3 and H4 N-terminal tails at the core promoter.
**Experimental procedures**

**Plasmids and solid-phase DNA templates**

AFP/lacZ contains 3.8 kb upstream DNA including proximal and distal promoter and enhancer I, fused to the coding region of β-galactosidase (11). DelA/lacZ is identical except that it contains a 10 base pair deletion in one p53 binding half site between -850 and -840, as well as a 4 bp mutation in the other half site. It was constructed by PCR mutation of the previously described AFP/mut5 template (6). Solid-phase AFP/lacZ and DelA/lacZ templates were coupled to streptavidin-coated paramagnetic beads as described (12). The chick adult β-globin plasmid, pUC18ABC/Δ1, contains the entire promoter, coding sequence and 3’ enhancer (13).

**Protein expression and cellular extracts**

Cell extracts were prepared from HeLa and HepG2 (AFP positive, ATCC catalog number HB-8065) cells as described by Dignam et al. (14) with minor modifications (6). All extracts contained total proteins in concentrations of 5-10 mg/ml. *Xenopus* egg extract high-speed supernatant (HSS) was prepared as described previously (15). Constitutively activated, recombinant p53 protein was expressed from p53Δ30his as previously detailed (16).

**Chromatin assembly and in vitro transcription**

*In vitro* chromatin assembly and transcription reactions were performed as reported (12). When trichostatin-A (TSA, Sigma Chemical Co.) was added to inhibit endogenous histone deacetylases in the *Xenopus* egg HSS, the 10 mM DMSO stock solution was diluted to the desired final concentration and incubated with HSS on ice for 10 minutes prior to bead/DNA addition and chromatin assembly. For post-chromatin assembly additions, proteins were added after the one-hour chromatin assembly period and incubated for an additional 30 minutes. Chick β-globin DNA template was added as a control for RNA recovery. Results were quantified by ImageQuant analysis of scanned autoradiograms.

**Restriction enzyme accessibility**
Hinc II restriction enzyme accessibility experiments were performed as described (17). All restriction enzyme digests were run on a 2% agarose gel and Southern blotted. A 23 bp $^{32}$P-endlabeled oligomer corresponding to promoter sequence at +4 to +26, 5'-CCCACCTCCAGCCTGCCTGCGG-3', was used as probe.

**Acetylated histones H3 and H4 antibodies**

The N-terminal 24 amino acids of human N-acetyl-lysine modified (4, 9, 14, 18, 23)-H3 and (5, 8, 12, 16, 20)-H4 were synthesized as tetrameric multiply antigenic peptides (MAP) by Research Genetics, inc. (Birmingham, AL). Non-acetyl immunoreactive antibodies were removed by subtracting with a synthetic, N-terminal non-acetylated mixture of H3 or H4 peptides. Finally, antibodies were affinity purified using AcH3 and AcH4 MAP. Specificity was confirmed by Western blot analysis, under standard conditions, of histones purified by sodium butyrate treatment and fractionated by acid gel electrophoresis.

**Chromatin immunoprecipitation**

Chromatin immunoprecipitation (ChIP) assays were performed on *in vitro* chromatin assembled DNA templates. Protein/DNA complexes were cross-linked by exposure to 1% formaldehyde (final concentration) for ten minutes at room temperature, followed by 50 minutes on ice. These reactions were diluted three-fold in *Xenopus* egg extract buffer (12) and mixed gently. The supernatant was removed after magnetic concentration, and bead/DNA was resuspended in 1X SM2 buffer (500 mM Sucrose, 80 mM KCl, 20 mM HEPES, pH 7.5, 3.5 mM ATP, 6 mM CaCl$_2$) plus 1.5 U micrococcal nuclease (MNase, Boehringer Mannheim) (12). A five minute incubation with MNase digested cross-linked chromatin into 200-500 nucleotide size fragments, as determined empirically by agarose gel electrophoresis and Southern blotting. After stopping digestions in 20 mM EDTA/2 mM EGTA (final concentration), 9 volumes of ChIP dilution buffer (16.7 mM Tris-HCl, pH 8.1, 167 mM NaCl, 1.1% Triton X-100, 0.01% SDS, 1.2 mM EDTA) were added to each sample. This diluted sample of chromatin/protein/DNA fragments was removed as a supernatant from the immobilized paramagnetic beads and divided among several reaction tubes for incubation with
control and specific antibodies as described (18). The presence of immunoprecipitated DNA sequences was determined by Southern blotting using a slot-blot manifold for binding DNA to GeneScreen Plus membrane (Beckman Chemical Co.). Hybridization with $^{32}$P-endlabeled, double-stranded oligomers encompassing AFP/lacZ sequences from +4 to +26 (promoter probe), from -860 to -830 (p53 binding site) and random-primed labeled full-length template was performed as described (17). Results were quantified by ImageQuant analysis of scanned autoradiograms. Values are expressed as a ratio of bound to input, corrected by comparison to no antibody and full-length template controls.

Results

p53 binding mediates transcriptional repression and chromatin structure alteration

We employed in vitro chromatin assembly of solid-phase AFP DNA templates to reconstitute repression of AFP transcription through a distal p53-regulatory element. We showed previously that chromatin assembly by this method establishes physiologically spaced nucleosomes over the entire DNA template and renders in vitro transcription tissue-specific, in contrast to nucleosome-free DNA (12,17). These templates were either transcribed for functional analysis or structurally analyzed for promoter accessibility or histone modification status (Fig. 1A). Nucleosome assembly silences AFP transcription compared to unassembled DNA templates (Fig 1B, lane 1 compared to β-globin transcripts). Addition of HepG2 extract, prepared from cultured human hepatoma cells that express AFP, during chromatin assembly derepresses and/or activates AFP transcription an average of five-fold (lane 2). Titration of increasing amounts of recombinant p53, in addition to HepG2 extract, during chromatin assembly represses AFP chromatin transcription up to 3-fold (lanes 6 and 7). However, p53 introduced after chromatin structure was established had no significant effect on transcription (p53$^{\text{post}}$, average of 1.1-fold increase, lanes 3-5).

We have utilized restriction enzyme accessibility to monitor changes in promoter chromatin structure induced by p53 DNA binding (Fig. 2). Hinc II restriction digestion at sites that flank
the AFP promoter at -55 and +29, Fig. 2A, correlates with a core promoter region relatively free of a bound nucleosome and open to transcription complex assembly (12,17). Structural analysis mirrored the functional effects of p53 addition both during and post-chromatin assembly (Fig. 2B). Compared to chromatin assembly in buffer only, HepG2 extract established an open core promoter (lane 3 compared to lane 2). Addition of p53 protein during chromatin assembly revealed a dose-dependent chromatin closure (lanes 4-6, compared to lane 3). The core promoter chromatin structure remained relatively inert to p53 protein addition post-assembly (lanes 7 and 8). A quantitative average of these data and similar experiments are graphed in Fig. 2C. Comparison of both transcription and chromatin structural consequences of p53 addition pre- and post-chromatin assembly, support the view that p53 action is primarily at the level of chromatin structure organization rather than targeting modification of an established chromatin structure.

The p53 DNA binding site within the AFP upstream region (-860/-830, Fig. 3A) fits the consensus binding sequence for a p53 tetramer at the 5' half (PuPuPuCA/TA/TGPyPyPy, (19)). However, this p53 repressor element has a 3' half site following a 3 base-pair nucleotide spacer that deviates from consensus (PyPyPyCTAGPuPyPu). The influence of DNA binding sequence on p53 conformation and function has been previously described (20), but the specific way in which this response element dictates p53 regulation of AFP is not known. Deletion and mutation of the p53-binding site (DelA) abolishes both p53 and HNF-3 binding at this site (data not shown). Consistent with lack of p53 binding, repression of chromatin transcription (Fig. 3B) and structure accessibility at the core promoter (Fig. 3C) are lost.

**Histone modification does not alter p53-mediated restriction of promoter accessibility**

Nucleosome positioning, which restricts core promoter access to restriction enzymes and transcription preinitiation complexes, may be affected by histone N-terminal tail interactions with DNA. Chromatin composed of highly acetylated histones, in general, may be more dynamic and readily activated for transcription; whereas, the opposite may be true for under-
acetylated nucleosomes. Multiple transcription factors interact with protein complexes displaying intrinsic enzymatic activity, such as histone acetyl transferases (HAT's) or histone deacetylases (HDAC's), and target modification of chromatin by virtue of their DNA binding ability (recently reviewed in 21,22,23). Several studies have shown interactions between both HAT and HDAC complexes and p53, interactions that may promote histone modification, p53 modification or p53 stabilization (24-30). Our baseline study of histone modification at the core promoter and the p53 binding site at -850 revealed no significant variation in histone H3 acetylation between these regions, in the presence or absence of p53. Four separate ChIP experiments were performed and the percent of acetylated histone H3 present at these regions averaged: at the core promoter, 27.8% +/- 9.3 (in the absence of p53) and 27.6% +/-9.2 (in the presence of p53); and at the p53 binding site, 35.1% +/- 5.7 (-p53) and 32.2% +/- 5.9 (+p53).

Although there were no significant variances between histone modification states localized at the core promoter or p53-binding site, there were striking differences in acetylation states when the equilibrium between acetylases and deacetylases was shifted by addition of TSA to Xenopus egg extract in the absence of hepatoma proteins (Fig. 4). In response to increasing concentration of TSA, nucleosomes present at the core promoter region increased in both H3 and H4 acetylation 2-3 fold. However, in the local region of p53 binding, histone modification was maintained at a baseline level over the concentration range of TSA (Fig. 4A). Somewhat surprisingly, the presence or absence of p53 protein made little difference to the state of histone modification at all levels of TSA. Thus, we find no evidence that p53 alone targets modification of histone tails at the p53-binding site or at the core promoter.

The specific increases in histone H3 and H4 acetylation at the core promoter led directly to derepression of transcription in the absence of any exogenous activator proteins, Fig. 4B. Functionally, the 2-3 fold changes in histone acetylation at the core promoter mediated a two-fold increase in transcription of chromatin assembled in Xenopus egg extract treated with TSA (lanes 1-5). The increase in transcription was not dependent on the p53/HNF3 binding site, as
similar transcription of the DelA AFP template in TSA-treated egg extract also showed transcription increase with increasing TSA (Fig. 4C, lanes 2 and 3 compared to 1).

Despite the presence of highly acetylated histones at the core promoter, p53 was able to repress transcription fully when added during chromatin assembly (Fig. 4B, lane 7 compared to lanes 1 and 6). The ability to repress chromatin transcription was absolutely dependent on DNA binding of p53 as the DelA AFP template remained transcriptionally active in the presence of p53 (Fig. 4C, lanes 4 and 5). Restriction accessibility analysis of core promoter chromatin (Fig. 4D) showed a parallel increase of two-fold in the presence of TSA (lane 3), and repression to baseline levels in the presence of added p53 (lanes 4 and 5), both in parallel with effects on transcription function (Fig. 4B). The ability of p53 to modify nucleosome/DNA interactions at the core promoter, resulting in chromatin structure closure and repression of transcription, is not dependent on tissue-specific factors or targeted modification of histone acetylation, and occurs even in the presence of highly acetylated nucleosomes.

**Discussion**

During hepatic development and post-natal silencing of AFP expression, specific changes in chromatin structure of the AFP gene occur, which likely play a role in regulation (31,32). Our present study reveals that the functional outcome of p53 DNA binding within the AFP distal repressor region is dictated by chromatin structure organization. Chromatin structure can influence transcription regulation by obstructing transcription factor access to DNA or by facilitating interactions between distal regulatory factors and proximal promoter elements to repress or activate transcription (33-38). Our *in vitro* chromatin transcription system recapitulates distal regulation of AFP transcription by p53 bound to DNA 850 base pairs 5’ of the transcription start site within the AFP developmental repressor domain. As best studied in *Drosphila*, distal repressors, like distal enhancers, are essential in regulation of development and differentiation (39).
Proteins that interact with DNA regulatory elements dictate chromatin activation or repression, as well as the consequences of p53 regulation. AFP chromatin is derepressed or activated in the presence of hepatoma extract, but remains transcriptionally repressed when assembled in HeLa extract (17). As shown here, p53 mediates repression of hepatoma-activated chromatin, but in the presence of HeLa extract a low level of transcription activation is observed instead (40). Thus, the interpretation of p53 protein interaction with DNA, whether activating or repressing chromatin structure, is influenced by multiple trans-acting factors. The timing of these interactions relative to chromatin assembly is important as well. We find that p53 lacks the ability to alter an established, activated chromatin structure. HNF-3 (FoxA) protein, present in the HepG2 extract, mediates core accessibility to Hinc II restriction enzyme and basal transcription factors in chromatin transcription (17). Zaret and coworkers established that HNF-3 is an architectural transcription factor that can position nucleosomes along the albumin enhancer, rendering it competent for later trans-activator binding (41,42). Thus, HNF-3 acts as primary effector of chromatin modification and derepression, and this established chromatin structure cannot be altered by post-assembly addition of p53. Previous investigations revealed that p53 binding to DNA induces considerable bending and twisting at its binding site, and the inherent sequence-dependent form that DNA assumes greatly affects p53 DNA binding properties (43). The manipulation of DNA and chromatin structure by proteins such as HNF-3 and/or p53 may establish a requisite order of transcription factor binding to induce specific chromatin-repressed or -activated forms. Studies of Swi5p-mediated recruitment of Swi/Snf and SAGA complexes at the yeast HO endonuclease gene promoter (44), as well as temporal recruitment of chromatin remodeling and histone modifying complexes by nuclear receptors (45), support the idea that only specific transcription factors can interact with chromatin to initiate a series of regulatory steps. This temporal order is likely influenced by flanking DNA sequence, the complexity of the regulatory element(s) and interacting proteins.

Our results showing that p53 cannot bind and repress a previously activated chromatin template are in contrast to p53 action at a chromatin-repressed (assembled in buffer) p21 gene
template (46). In this case, p53 can bind to chromatin and target p300 to acetylate histone tails at a p53-binding site, which then spreads distally to the core promoter. Together, p53 and p300 activate transcription of chromatin-repressed p21 gene templates. The ability of p53 protein to target histone modification was also suggested by previous studies. Transcription repression of the MAP4 gene is correlated with p53-mediated histone deacetylation and promoter-localized histone modification in cultured cells (24). Our studies of histone modification revealed little change in histone acetylation mediated by p53 addition during chromatin assembly in untreated Xenopus egg extract. When the equilibrium between histone acetylase and deacetylase activities was shifted toward acetylation by TSA addition, the p53 binding site region was maintained in a state of reduced acetylation, even in the absence of exogenous p53, compared to the core promoter. We propose that local histone modification at the AFP repressive p53-binding site is maintained by multiple protein complexes (S. Ogden and M. Barton, unpublished results). Regional, regulated shifts in acetylation/deacetylation equilibria may be revealed by disruption of histone acetylase or deacetylase activities (47), which exist endogenously in Xenopus egg extract.

Despite increased histone acetylation, p53 regulates chromatin structure alteration that creates inaccessibility at the AFP core promoter. The ability of p53 to modify chromatin structure at the core promoter is not dependent on the presence of hepatoma-specific factors, and is inhibited when tissue-specific factors have previously established active chromatin. Our studies reveal a hierarchy of transcription regulation by p53 in which distal alterations in chromatin structure rather than local modification of histone tails play a key role in repressing AFP gene expression. It will be of great interest to compare other p53-repressed and -activated genes and establish if the interpretation of p53 induction as a transcription activation or repression signal is dictated by DNA regulatory site complexity, interacting proteins and consequent chromatin structure alteration.
Acknowledgements

We thank C. Florio for technical assistance with ChIP protocols and antibody characterization and A. J. Crowe for generous help in methodology, insightful discussions and critical reading. This work was supported in part by a grant from NIH (GM53683) to M.C.B. A NIH predoctoral training grant (T32 CA59268) and a Ryan Foundation Fellowship provided support for S.K.O.
References


**Figure legends**

**Figure 1.** p53 represses AFP chromatin transcription *in vitro*.  
**A. Solid-phase chromatin assembly.** Chromatin is assembled in the presence of proteins, extracts and/or buffer for one hour prior to magnetic concentration, washing and removal of unbound proteins. Chromatin templates are then transcribed or analyzed for chromatin structure accessibility. **B. Transcription analysis of p53 added during chromatin assembly or after chromatin assembly.** 500ng of AFP/lacZ template DNA were incubated in buffer only (lane 1) or with HepG2 extract, lanes 2-7, and 0 (-, lane 2), 150ng (+, lane 3), 300 ng(++, lanes 4 and 6), or 450ng (+++, lanes 5 and 7) p53 and transcribed. p53 was added either prior to chromatin assembly (lanes 6 and 7) or after chromatin assembly was completed (lanes 3-5). Molecular weight standards (MW) were radiolabeled φx174 HaeIII digestion reaction (Gibco BRL). ß-globin serves as an RNA recovery control.

**Figure 2.** p53 organizes chromatin structure.  
**A. Core promoter accessibility assay.** The core promoter of AFP has HincII sites at -55 and +29. Digestion of chromatin with Hinc II releases an 84 bp fragment only when both sites are accessible. The ovals represent nucleosomes bound at the AFP promoter: dashed ovals are nucleosomes that obstruct enzyme digestion and, presumably, transcription factor binding. **B. Restriction enzyme probing of chromatin structure.** Hinc II accessibility analysis was performed on chromatin assembled templates. Chromatin-free DNA (lane 1) and chromatin-assembled DNA (lanes 2-8) were preincubated with p53 (lanes 4, 5 and 6; 75, 150 and 300 ng, respectively) or p53 was added after assembly (lanes 7 and 8, 150 and 300 ng, respectively) in the presence of HepG2 extract (lanes 3-8). Uncut DNA is present is lane 9. **C. Graphic representation of transcription activation and promoter accessibility.** The quantitative averages of at least two separate assays for p53-regulated transcription (open boxes) and promoter accessibility (shaded boxes), added prior to (pre) or after (post)
chromatin assembly, are compared to HepG2 activated chromatin assembled in the absence of p53. Concentrations of p53 are 1x, 150 ng, and 2x, 300 ng.

**Figure 3. DNA binding is required for p53 function.** A. A mutated AFP template. The -860 to -830 sense strand of AFP is depicted with the p53 binding site (consensus 5’ half site, solid line, and non-consensus 3’ half site, dashed line) marked above the normal DNA sequence (AFP) and the HNF-3 site below mutated p53 sequence (DelA). DelA lacks the nucleotides indicated by hyphens and has altered bases in lower case letters. B. **p53 binds to DNA to repress transcription.** AFP (lanes 1-5) and DelA (lanes 6-9) bead-DNA were transcribed *in vitro* as chromatin-free (lane 1) and -assembled (lanes 2-9) templates. Chromatin was assembled in the presence of buffer (lanes 2 and 6), HepG2 extract (lanes 3-5 and 7-9), plus p53 protein (lanes 4 and 8, 150 ng; lanes 5 and 9, 300 ng). C. **p53 binds DNA to alter core promoter accessibility.** AFP (lanes 1-5) and DelA templates (lanes 6-10) were incubated in buffer (lanes 5 and 10) or chromatin assembled (lanes 1-4 and 6-9) as described above. HepG2 extract (lanes 2-5, 7-10) was supplemented with 150 (+, lanes 3 and 8) and 300 (++, lanes 4 and 9) ng of p53 during assembly. Southern blot analysis reveals relative HincII accessibility of chromatin (84 bp HincII band).

**Figure 4. p53 mediated repression of AFP transcription occurs even in the presence of hyperacetylated histones at the core promoter.** A. **Addition of TSA promotes hyperacetylation of histones H3 and H4 at the AFP core promoter but not at the p53 binding site.** ChIP analyses of H3 (white bars) and H4 (shaded bars) acetylated histone populations present at the core promoter region (open bars) and the p53 binding region (hatched bars) were performed on *in vitro* chromatin assembled AFP templates in the presence (+, 300 ng) or absence (-) of p53. Chromatin was assembled in *Xenopus* egg extract, incubated in increasing amounts of TSA: none, 10 nM, 100 nM and 3 µM. Histone acetylation levels
were expressed as a ratio compared to baseline values determined in the absence of TSA (see text). These TSA titration experiments were performed twice, thus standard deviation values are not presented. **B. Histone hyperacetylation leads directly to derepressed chromatin transcription that is silenced by p53 addition.** *Xenopus* egg extract incubated in the presence of 0, 10 nM, 100 nM, 3 µM and 10 µM TSA was used to assemble AFP bead-DNA into chromatin and transcribed (lanes 1-5, respectively). p53 (300 ng) was added during chromatin assembly (lanes 6 and 7) in egg extract incubated in the presence of 0 (lane 6) or 3 µM TSA (lane 7). RNA recovery control primer extension analysis of added β-globin DNA template was performed separately on these reactions (small gel insert). **C. p53-mediated silencing of TSA-derepressed transcription requires DNA binding.** DelA bead-DNA was assembled in chromatin as described above, using *Xenopus* egg extract incubated in the presence of 0 (lane 1), 3 µM (lanes 2, 4 and 5) and 10 µM (lane 3). p53 protein was added during chromatin assembly (lane 4, 150 ng; and lane 5, 300 ng). **D. p53 mediates core promoter closure even in the presence of hyperacetylated histones.** HincII restriction accessibility was performed on AFP templates in the absence of chromatin assembly (lane 1) or when assembled into chromatin (lanes 2-5). Chromatin was assembled in *Xenopus* egg extract incubated in no TSA (lane 2) or 10 µM TSA (lanes 3-5). Addition of p53 (+, 150 ng, lane 4; ++, 300 ng, lane 5) altered chromatin accessibility to HincII enzyme.

---

1 Abbreviations: AFP (alpha-fetoprotein), TSA (trichostatin-A), HSS (high speed supernatant), ChIP (chromatin immunoprecipitation), HAT (histone acetyl transferase), HDAc (histone deacetylase), MAP (multiply antigenic peptide), MNase (micrococcal nuclease)
Figure 1

A. 

\[ \begin{align*} 
\text{bead-DNA} & \xrightarrow{\text{p53 or buffer}} \text{Chromatin assembly} \xrightarrow{\text{pol II extract}} \text{P53 or buffer} \\
\text{buffer or extract} & \xrightarrow{\text{Xi egg extract}} \text{Post} & \text{Transcription analysis} \\
\text{wash} & \xrightarrow{\text{NTPs}} \text{β-globin DNA} & \text{Structural analysis} \\
& \xrightarrow{\text{Hinc II enzyme}} \text{ChiP analysis} 
\end{align*} \]

B. 

<table>
<thead>
<tr>
<th></th>
<th>hepatoma</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>MW</th>
</tr>
</thead>
<tbody>
<tr>
<td>p53/assembly</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>chromatin</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
</tbody>
</table>

β-globin

AFP
Figure 2

A. 

84 bp Hinc II released DNA

B. 

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
</tr>
</thead>
<tbody>
<tr>
<td>hepatoma</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>p53/assembly</td>
<td>-</td>
<td>-</td>
<td>+/2</td>
<td>pre</td>
<td>+</td>
<td>+</td>
<td>post</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>chromatin</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>uncut</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C. 

Fold increase in accessibility

84 bp HincII
Figure 4

A.  

![Graph showing fold increase in acetylation with different TSA concentrations.]

B.  

![Image of gel with bands labeled as AFP and β-globin.]

C.  

<table>
<thead>
<tr>
<th>p53</th>
<th>-</th>
<th>-</th>
<th>-</th>
<th>+</th>
<th>++</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSA</td>
<td>-</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

MW 1 2 3 4 5

D.  

<table>
<thead>
<tr>
<th>Chromatin</th>
<th>-</th>
<th>+</th>
<th>+</th>
<th>+</th>
<th>+</th>
</tr>
</thead>
<tbody>
<tr>
<td>p53</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>TSA</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

84 bp HincII
p53 targets chromatin structure alteration to repress alpha-fetoprotein gene expression
Stacey K. Ogden, Kathleen C. Lee, Kara Wernke-Dollries, Sabrina A. Stratton, Bruce Aronow and Michelle Craig Barton

J. Biol. Chem. published online September 25, 2001

Access the most updated version of this article at doi: 10.1074/jbc.C100381200

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts